» Articles » PMID: 19945406

Prevention of Steatosis by Hepatic JNK1

Overview
Journal Cell Metab
Publisher Cell Press
Date 2009 Dec 1
PMID 19945406
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic steatosis (fatty liver) is a major cause of liver dysfunction that is associated with insulin resistance and metabolic syndrome. The cJun NH(2)-terminal kinase 1 (JNK1) signaling pathway is implicated in the pathogenesis of hepatic steatosis and drugs that target JNK1 may be useful for treatment of this disease. Indeed, mice with defects in JNK1 expression in adipose tissue are protected against hepatic steatosis. Here we report that mice with specific ablation of Jnk1 in hepatocytes exhibit glucose intolerance, insulin resistance, and hepatic steatosis. JNK1 therefore serves opposing actions in liver and adipose tissue to both promote and prevent hepatic steatosis. This finding has potential implications for the design of JNK1-selective drugs for the treatment of metabolic syndrome.

Citing Articles

Multi-tissue network analysis reveals the effect of JNK inhibition on dietary sucrose-induced metabolic dysfunction in rats.

Yang H, Zhang C, Kim W, Shi M, Kiliclioglu M, Bayram C Elife. 2025; 13.

PMID: 39932177 PMC: 11813226. DOI: 10.7554/eLife.98427.


Absence of MCJ/DnaJC15 promotes brown adipose tissue thermogenesis.

Cicuendez B, Mora A, Lopez J, Curtabbi A, Perez-Garcia J, Porteiro B Nat Commun. 2025; 16(1):229.

PMID: 39805849 PMC: 11730624. DOI: 10.1038/s41467-024-54353-4.


Remodeling p38 signaling in muscle controls locomotor activity via IL-15.

Folgueira C, Herrera-Melle L, Lopez J, Galvan-Alvarez V, Martin-Rincon M, Cuartero M Sci Adv. 2024; 10(33):eadn5993.

PMID: 39141732 PMC: 11323882. DOI: 10.1126/sciadv.adn5993.


The serine phosphorylations in the IRS-1 PIR domain abrogate IRS-1 and IR interaction.

Woo J, Bae S, Wales T, Engen J, Lee J, Jang H Proc Natl Acad Sci U S A. 2024; 121(17):e2401716121.

PMID: 38625937 PMC: 11046688. DOI: 10.1073/pnas.2401716121.


MKP1 promotes nonalcoholic steatohepatitis by suppressing AMPK activity through LKB1 nuclear retention.

Qiu B, Lawan A, Xirouchaki C, Yi J, Robert M, Zhang L Nat Commun. 2023; 14(1):5405.

PMID: 37669951 PMC: 10480499. DOI: 10.1038/s41467-023-41145-5.


References
1.
Bonny C, Oberson A, Negri S, Sauser C, Schorderet D . Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes. 2001; 50(1):77-82. DOI: 10.2337/diabetes.50.1.77. View

2.
Weston C, Davis R . The JNK signal transduction pathway. Curr Opin Cell Biol. 2007; 19(2):142-9. DOI: 10.1016/j.ceb.2007.02.001. View

3.
Cortez-Pinto H, Carneiro de Moura M, Day C . Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol. 2005; 44(1):197-208. DOI: 10.1016/j.jhep.2005.09.002. View

4.
Das M, Jiang F, Sluss H, Zhang C, Shokat K, Flavell R . Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc Natl Acad Sci U S A. 2007; 104(40):15759-64. PMC: 2000443. DOI: 10.1073/pnas.0707782104. View

5.
Yang R, Wilcox D, Haasch D, Jung P, Nguyen P, Voorbach M . Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J Biol Chem. 2007; 282(31):22765-74. DOI: 10.1074/jbc.M700790200. View